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Abstract
Background: Relatively little is known about parents’ or children’s attitudes toward recruitment for, and
participation in, studies of new diabetes technologies immediately after diagnosis. This study investigated
factors affecting recruitment of participants for studies in newly diagnosed youth with type 1 diabetes.
Methods: Qualitative focus group study incorporating four recorded focus groups, conducted in four out-
patient pediatric diabetes clinics in large regional hospitals in England. Participants comprised four groups
of parents (n = 22) and youth (n = 17) with type 1 diabetes, purposively sampled on the basis of past in-
volvement (either participation or nonparticipation) in an ongoing two-arm randomized trial comparing
multiple daily injection with conventional continuous subcutaneous insulin infusion regimens from the onset
of type 1 diabetes.
Results: Stress associated with diagnosis presents significant challenges in terms of study recruitment, with
parents demonstrating varied levels of willingness to be approached soon after diagnosis. Additional challenges
arise regarding the following: randomization when study arms are perceived as sharply differentiated in terms
of therapy effectiveness; burdens arising from study participation; and the need to surrender new technologies
following the end of the study. However, these challenges were mostly insufficient to rule out study partici-
pation. Participants emphasized the benefits and reassurance arising from support provided by staff and fellow
study participants.
Conclusions: Recruitment to studies of new diabetes technologies immediately after diagnosis in youth
presents significant challenges, but these are not insurmountable. The stress and uncertainty arising from
potential participation may be alleviated by personalized discussion with staff and peer support from fellow
study participants.
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Introduction
Anumber of challenges surround studies of new diabetestechnologies in youth, especially as children’s involve-
ment in medical research is likely to include the involvement
of, and in many cases obtaining consent from, parents or legal
guardians. Children’s participation in medical research raises
important ethical issues, including children’s inherent vul-
nerability and, for adolescents in particular, the challenges
arising from major psychological and physiological changes
occurring during research participation.1 Previous research
has also emphasized the complexity of parents’ roles in terms
of their children’s research participation. A number of tensions
arise in this context, such as that between parents seeking to
take responsibility for their child’s well-being, on one hand,
and surrendering their child’s well-being to medical staff
during trials and/or standard care, on the other hand.2 Research
has shown that parents who lack understanding of research
concepts such as randomization may be less likely to allow
their children to participate in randomized trials and that par-
ents of children randomized to control arms of randomized
trials experience significant levels of disappointment—one of
many factors that can limit future research participation.2–7
For parents of children with newly diagnosed type 1 diabe-
tes, these general issues surrounding research participation are
supplemented by a number of condition-specific challenges.
Randomized trials investigating the impact of technological
treatments on disease progression frequently necessitate the
recruitment of children immediately after diagnosis. However,
this period is a highly stressful time for children and parents,
typically occurring with little warning and requiring multiple
significant life changes in a very short time frame, with the
threat of significant long-term morbidity, including micro-
and macrovascular complications.8,9 One study indicated
that 51% of mothers and 41% of fathers of children newly
diagnosed with type 1 diabetes met some or all of the di-
agnostic criteria for posttraumatic stress disorder as defined
by the Diagnostic and Statistical Manual of Mental Dis-
orders (DSM-IV).10 Parental stress arises from a number of
possible sources, including traumatic events (e.g., hospi-
talization) surrounding the onset of type 1 diabetes, the
threat of significant morbidity arising from the condition,
and parental responsibility in terms of caring for a child with
diabetes.10 The self-care regimens required for intensive
insulin therapy are complex and can lead to diabetes-based
parent–child conflict, particularly when parental involve-
ment in care (e.g., to reduce the risk of hypoglycemia)
conflicts with adolescents’ developing sense of autonomy.11
Thus, both generic and condition-specific challenges con-
front parents and children when considered as potential par-
ticipants in studies incorporating new diabetes technologies. As
yet, however, relatively little is known about how potential
participants feel about participating in randomized trials of
diabetes technologies in newly diagnosed youth with type 1
diabetes. The purpose of the present study was to gather qual-
itative information from parents and children with type 1 dia-
betes about their experiences of participation in an ongoing
randomized study (multiple daily injection [MDI] vs. contin-
uous subcutaneous insulin infusion [CSII]) in which recruit-
ment took place immediately after diagnosis. In addition to
informing future study design through a deeper understanding
of factors affecting potential participants in randomized trials
incorporating new diabetes technology, the present work can be
considered as part of wider efforts to explore psychosocial as-
pects of technology usage in diabetes care and parents’ expe-
riences of caring for children using diabetes technologies.12–14
Methods
Focus groups were conducted with parents and children
with type 1 diabetes in four pediatric outpatient clinics based
in large regional hospitals in England. Participants were re-
cruited on the basis of their involvement with an ongoing
study, which involves randomization to either MDI or CSII
pump therapy immediately after diagnosis. A heterogeneous
composition of parents and children, and of participants and
nonparticipants in the ongoing study, was chosen to elicit a
variety of perspectives and experiential knowledge (e.g.,
knowledge arising from experience of diagnosis as a child or a
parent).15 Each discussion was facilitated by members of the
study team (C.F. for focus groups 1–2, M.T. and J.A. for
groups 3–4), using a semistructured topic schedule devised by
the study team in light of preceding scientific literature.1–8,10
Focus group discussions were digitally recorded (with partic-
ipants’ consent), independently transcribed by a trusted
agency, and analyzed using a thematic analysis approach.16
Results
The four focus groups (FG1–FG4) averaged 58 min (53–
68 min) and included between 8 and 12 focus group partici-
pants, with an average of 10 focus group participants (on
average 6 parents and 4 children) with a range of demo-
graphic characteristics (Table 1). The majority of focus group
participants (n= 32) had chosen to participate in the ongoing
study, but a minority (n= 7) had chosen not to participate.
Three principal themes—recruitment, randomization, and
peer support—were identified through analysis of the focus
group transcripts, relating to specific aspects of participants’
previous experience of participation in a recent randomized
trial. These themes are described below with anonymized
quotations from parents and children from the four focus
groups (FG1–FG4).
Recruitment
Participants in all focus groups acknowledged the emotional
challenges and stress surrounding diagnosis, and consequently
the difficulties of signing up to a study and understanding its
pros and cons at the same time as coping with significant
informational burdens arising from diagnosis. In this context,
one parent remarked:
It is a bit of a shock when it’s that soon.We had to agree
within 10 days of diagnosis and your head’s still spinning
from the shock of the diagnosis really.
FG1
Other parents, however, suggested that it was good to ap-
proach patients early, either because the possibility of being
randomized to pump therapy was a possible ‘‘light at the end
of the tunnel’’ in the midst of a welter of confusing new
information (FG4) or because there was more time to process
information in the initial hospital stay than when children had
returned home later: ‘‘when [we were] in hospital. there’s
time to sit around and read the stuff and take it all in’’ (FG3).
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As such, there are clearly important differences in individual
preferences and capacity to absorb complex information.
Some participants suggested that more detailed discussion
of the pros and cons of the study would have been useful in
the initial stages. In FG2, for example, one parent described
the apparent unwillingness of staff to state clearly the pur-
poses of the study and the possible pros and cons:
[W]e were asked as soon as we’d been diagnosed whether we
wanted to participate in a study which would have a 50/50
chance of going on a pump or staying on injections, and then
when we asked which one’s better, a lot of people in the medical
profession couldn’t tell us one way or the other. [T]hey’re
very careful about not overloading you with too much infor-
mation. but if you need a decision. [you’re] just going to
have to jump in feet first and give a little bit more information.
In light of this, participants suggested that a personal ap-
proach could assist understanding: ‘‘I think you’re so bam-
boozled, I’m not sure what you could do to unbamboozle [sic]
the whole situation. a nice chat might tip the balance either
way’’ (FG2). In this context, many participants highlighted
their preference for personal interactions with medical staff
as opposed to other resources such as study leaflets or mul-
timedia. For example, one parent stated that
I think when you’re in that situation with a poorly child, you
just take whatever the doctor says.Wasn’t there a DVD or
something to watch?. I don’t think we’ve ever watched it.
FG1
Parents mentioned the additional difficulty of attempting to
involve children in decision-making while acknowledging their
relative lack of understanding of research and its importance:
‘‘Most children don’t know what. a medical trial or research
trial is so.They’re just taking in the diabetes and I don’t think
they would understand what is meant’’ (FG4). Another parent
in the same group suggested that it should not be assumed that
children themselves should decide whether to participate or
not, seeming to imply that while he thought his child was able
to make a good decision and withstand the possible disap-
pointment of randomization, other children may not:
No disrespect, I’m talking about the general public now, if
I was the father of another child. dare I say it, I wouldn’t let
it be the child’s decision, in some cases.
By contrast, another parent (also in FG4) stated: ‘‘It sounds
like we all left the decision up to the child, at the end of the
day. You can only tell [them] what you think the benefits, the
pros and cons are.’’ It should be noted however that earlier in
this group discussion, it appeared that two children at least
would not have participated without their parents’ encour-
agement, and parents in this group also suggested that
children do not understand what research is: ‘‘I just don’t
think he would have understood it all.’’ In FG1, one child
described themselves as ‘‘scared’’ about signing up to the
study, and that it was their parents’ decision rather than theirs.
Another child in the same group agreed, stating that her
parents had decided that she would participate since there
was ‘‘an overload of information’’ making it hard for her ‘‘to
understand what was happening.’’ Clearly there is a tension
between including children in decision-making, on one hand,
and overloading them with stressful information and respon-
sibilities, on the other hand.
Randomization
Many parents expressed significant concerns about this
aspect of their participation in the MDI versus CSII trial,
describing the potential disappointment of being randomized
to MDI as an additional burden to the informational chal-
lenges arising from diabetes. One parent in FG1 described the
experience as follows:
[The] flip of the coin came and [our daughter] ended up on
injections for 14 months, so she was disappointed she wasn’t
going to onto a pump, because the way it was sold to us it
would make [child’s name]’s life so much easier.
One parent described the randomization process as ‘‘frus-
trating’’, since you could ‘‘land either way’’:
It would have been better to have a choice, I understand why
not, but have a positive choice. rather than, I’ll go in and see
where the dice lands. on top of everything else it was just a
little bit more pressure.
FG2
In the specific trial they had experienced, participants’ frus-
tration and disappointment seem to have risen from a general
assumption, facilitated perhaps by discussions with staff re-
garding the benefits of the CSII arm, that the pump would be a
significantly better treatment option than MDI. In FG4, several
parents highlighted the need for trial staff to demonstrate
equipoise during recruitment. Specifically, these parents sug-
gested that it would be better if the medical staff described the
benefits of the pump in a ‘‘dull’’ manner to manage expecta-
tions and avoid raising (and possibly then dashing) partici-
pants’ hopes of obtaining this arm in randomization:
[D]on’t make it out to be as good as maybe what it is, so then if
you don’t get it, you’re not as disappointed. [W]hen you get
[the pump], then tell me how good it is, but until I get it, [I]
don’t want to know.
Parents also emphasized the importance of equipoise in terms
of issues arising at the end of the study for those randomized to
Table 1. Focus Group Participants
Focus
group
No. of focus
group
participants
Participation in trial Status Gender Age category
Y N Parent Child Male Female 0–9 10–18 19–35 36–52 53+
FG1 9 9 0 5 4 4 5 2 2 1 4 0
FG2 12 12 0 7 5 4 8 0 5 0 7 0
FG3 8 4 4 4 4 3 5 0 4 2 2 0
FG4 10 7 3 6 4 2 8 0 4 1 3 2
Total 39 32 7 22 17 11 24 2 15 5 16 2
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the ‘‘technological’’ arm (i.e., the CSII arm in the previous
study), when participants may have to return the new technol-
ogy having become aware of its benefits. One parent in FG4
expressed this concern with regard to worse glycemic control:
‘‘if the research is based on getting such great control for 2
years, woohoo, well, I’ve had 2 years of great control, and then
what?’’ A parent in FG1 suggested that children’s reaction to
this change might well be age-dependent: ‘‘I mean, children are
tolerant, they just take it in their stride, but a teenager would
really throw their toys out [of] the pram.’’ More positively,
some parents suggested that the eventual difficulties of ceasing
technology usage could be eased with more upfront discussion.
As one parent in FG2 stated:
Perhaps the more discussion the better, about the longer
term. not just about the immediate challenges of managing
the system., but also what happens at the end of the study.
Despite these concerns, there was a pragmatic recognition
from most parents that randomization is necessary for re-
search: ‘‘Needless to say the coin went up in the air and we
stayed with the injections, which is the way it works’’ (FG2).
The same parent went on to state that, in hindsight, the MDI
arm was a useful experience:
And actually with hindsight, I’m really glad that we had a year
of injections, because I think that was very beneficial, and
I think we learned an awful lot doing that.
As such, parents’ initial preference for a particular arm of a
given study may be overcome once benefits of the other arm
become apparent.
Moreover, some participants initially wished to be ran-
domized to MDI because the pump arm was seen as more
technically challenging. Thus, one child stated: ‘‘Just, like, it
seemed easier going on injections, because I knew more about
that than I did the pump’’ (FG1). Likewise, those who did use
a pump acknowledged that it was not necessarily an ‘‘easier’’
option, since it required new skills, in addition to raising
issues of visibility. One child whispered in her mother’s ear
that (as the mother subsequently related) ‘‘the thing she finds
hardest is people asking her what her pump is, and you know,
what’s that under your clothes. and she really cannot cope
with that at the moment’’ (FG1). Another child (speaking in
FG2) noted that they already had to carry quite a lot of things
to school and that additional burdens arising from diabetes
care were frustrating:
Well, I do have to bring quite a lot of things to school
but. carrying round the injections. and stuff, I have to
bring a bag and an extra bag on school trips. An extra bag
everywhere and it can be quite annoying.
Overall, there was recognition that no new technology can
be a panacea for all ills and will require some additional
investment in training and effort. These findings may be
significant in light of future trials involving yet more so-
phisticated closed-loop systems and in which equipoise re-
garding the two study arms may be yet more imperative (see
Discussion).
Peer support
When discussing support offered to them during trial
participation, parents uniformly emphasized the importance
of being able to contact clinicians directly for advice and
support both by e-mail and telephone. One parent in FG1
stated this view as follows: ‘‘it comes down to trust and, you
know, when you realise that somebody is [available] on the
phone all the time [and] that actually you can do anything
with that support. It’s knowing that support is there.’’
Others, however, suggested that medical staff may try to be
‘‘as impartial as possible and not try to influence which road
someone goes down’’ (FG2) and therefore that support and
advice from other parents and children would be valuable in
addition to clinical advice from healthcare staff. This was
often discussed in terms of the ability to access a pool of
previous participants who were willing to be contacted by
new participants, as one parent in FG3 stated:
I think it’s actually nice to see, I think as well from a parent’s
point of view, an actual person and kind of someone who’s
been through exactly the same that you’ve been through.
Another participant in FG3 noted that they would be happy to
form part of such a pool of experienced participants them-
selves, on the basis of their own experience of the lack of such
a system:
That [initial] four day period is awful, and I would have loved
to have seen someone who had been previously diagnosed and
sort of come in as a volunteer and say, we went through this
and we done that and just take away some of that doctor
talking to me, telling me it’s going to be okay, because
I believed [the doctor but] it’s an awful time.
One parent in FG2 suggested that children be included in
the pool of ‘‘buddies’’, since ‘‘as we all know, kids speak to
kids in a different language than kids to adults, they relate to
each other, so it may help the child if there’s any nervousness
there.’’ In this context, a child in FG2 stated: ‘‘I think it would
probably help if I could talk to someone who had done it
before to, like, reassure me’’. There are potential ethical is-
sues regarding child-to-child networks, but it seems clear that
there is significant appetite for a peer support or ‘‘buddy’’
system, which is a more active and interactive resource than
websites, videos, and leaflets. In this context, one parent in
FG2 stated explicitly that the existence of such systems
would encourage participation in research studies: ‘‘If that
was something that you were able to build in, I think it would
be quite a draw, actually.’’
Discussion
Participants in all four groups highlighted challenges arising
from children’s potential study participation soon after diag-
nosis, with particular reference to issues of recruitment and
randomization—challenges that led participants to suggest a
need for peer support during trials.
In terms of recruitment, participants generally saw diagnosis
as a stressful time characterized by information overload, but
disagreed regarding both the best time to approach families for
recruitment and the child’s role in decision-making. However,
a consensus emerged to the effect that more personal in-
teractions with healthcare professionals presented the best
opportunity to alleviate participants’ concerns regarding par-
ticipation.
In terms of randomization, participants highlighted the
potential disappointment arising from allocation to the con-
trol arm (in this case, MDI as opposed to CSII), especially in
cases in which research staff had failed to display equipoise
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regarding both trial arms. Participants saw equipoise as im-
portant not just in terms of minimizing disappointment for
those allocated to the control arm but also for those ran-
domized to the new technology arm (in this case, CSII), since
new technologies may be more difficult to use and often have
to be surrendered at the end of the trial. In light of these
challenges, both parents and children emphasized the need
for peer support systems to supplement clinical support, with
some participants also suggesting that they would be happy to
become peer supporters themselves.
These findings resonate with previous work on challenges
surrounding research participation, including both partici-
pants’ limited understandings of research procedures and the
potential for disappointment arising from randomization,2–7
and findings on psychosocial challenges arising from diag-
nosis of type 1 diabetes in youth.8–11 The strong focus on
personal interaction between trial participants and medical
staff echoes previous work that prioritizes personal interac-
tion over multimedia approaches (e.g., videos or computer-
ized presentations), or enhanced consent forms in terms of
improving participants’ understanding of medical research,17
and provides additional support for investment in staffing to
provide sufficient personnel for intensive personalized en-
gagements. Furthermore, participants’ expressions of their
desire for peer support systems are in line with previous re-
search demonstrating how such systems can constitute a
powerful adjunct to clinical support when patients are not in
contact with medical staff,18,19 although research also high-
lights the need to strike a balance between the independence
of peer support networks and the possibility of harmful ad-
vice being propagated without clinical moderation.18 Ethical
issues may also rise in the context of children’s expressed
desire for child-to-child peer networks alongside, or instead
of, parent-to-parent conversations.
In addition, our findings contribute a nuanced exploration
of the complexities of technology usage in diabetes studies,
thus reinforcing the well-attested need for equipoise in tri-
als.20 Participants’ concerns regarding randomization ranged
beyond the predictable initial disappointment that could arise
for those allocated to the control arm, and the equally pre-
dictable eventual disappointment for those in the other arm
who have to surrender new forms of technology at the end of
the study. While clinicians and technologists may be prone to
assuming that all or most participants will wish to be allo-
cated to the new technology arm, several participants in our
focus groups described the benefits they derived from allo-
cation to the MDI control arm, and in some cases stated that
they preferred this arm because of the technical challenges
posed by pump usage. Moreover, reflecting previous research
on the unpredictability of technology use21 and an emerging
awareness of the links between diabetes stigma and the aes-
thetics of medical devices,22 one child voiced her discomfort
at the social attention generated by her use of a pump that was
visible to others, while another discussed their reluctance to
carry additional diabetes equipment to school. Thus, equi-
poise in trials of new diabetes technologies should not only be
regarded as a standard aspect of recruitment but should be
founded on an in-depth awareness of the complexities of
patient interactions with diabetes technology. These com-
plexities are likely to present themselves with yet greater
urgency in future with regard to new closed-loop systems
(also referred to as ‘‘artificial pancreas’’, ‘‘bionic pancreas’’,
or ‘‘artificial beta cell’’ systems), which require users to in-
teract with multiple devices—typically, a continuous glucose
monitor, smartphone-mounted control algorithm, and wear-
able insulin pump.14,23–24 In trials involving these and other
new diabetes technologies, researchers should consider using
a range of trial design alternatives, including delayed
treatment and crossover designs, to minimize anticipated
stress arising from randomization and therefore maximize
the likelihood of participation.
Strengths and Limitations of This Study
We used a qualitative, in-depth focus group approach in-
volving 39 participants, giving a detailed understanding of
the experiences of parents and youth with newly diagnosed
diabetes. Participants also highlighted the need for intensive
personalized engagement with healthcare professionals and
equipoise regarding study arms. This research also showed
that parents and children placed strong emphasis on the im-
portance of ‘‘buddy’’ systems for peer support. However,
only a small minority of focus group participants had chosen
not to participate in the ongoing trial. Consequently, this
study did not explore in depth the views of parents and
children who opted not to participate in the ongoing ran-
domized trial. Ideally, future research would foreground and
investigate the views of nonparticipants to identify further
barriers to research participation, although ethical issues may
arise in this context (e.g., pursuing individuals and families
who have already opted out of research to seek consent for
further research participation).25 Future research could also
usefully compare baseline expectations with the details of
participant involvement during and after studies of new di-
abetes technologies, to clarify which specific factors may
have contributed to positive and/or negative experiences.
Conclusions
In conclusion, participants expressed a number of concerns
that arise with regard to the research participation of newly
diagnosed youth with type 1 diabetes, but also emphasized
the way in which these concerns could be alleviated by more
intensive personal interaction with healthcare professionals
and members of peer support networks. Our findings also
highlight the importance of equipoise regarding both arms of
studies involving new diabetes technologies. By investing in
these aspects of trials, research teams will be able to manage
participants’ concerns more effectively and thus minimize
the anxiety arising from research participation in studies
taking place soon after diagnosis.
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